Survival outcomes of east Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR tyrosine kinase inhibitors: A network meta‐analysis of …
HC Chang, KT Huang, CC Tseng, YM Chen… - Thoracic …, 2023 - Wiley Online Library
Background The comparative efficacies of different generation tyrosine kinase inhibitors
(TKIs) in epidermal growth factor receptor (EGFR)‐mutated advanced non‐small cell lung …
(TKIs) in epidermal growth factor receptor (EGFR)‐mutated advanced non‐small cell lung …
[HTML][HTML] Optimization of treatment strategies for elderly patients with advanced non-small cell lung cancer
Q Chen, S Ying, J Qin, L Zhang - Frontiers in Oncology, 2024 - ncbi.nlm.nih.gov
Lung cancer stands as a malignant neoplasm bearing the highest burden of morbidity and
mortality within the elderly population on a global scale. Among the lung cancer subtypes …
mortality within the elderly population on a global scale. Among the lung cancer subtypes …
Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
WC Kwok, JCM Ho, TCC Tam, MSM Ip… - Thoracic …, 2022 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
[PDF][PDF] Outcomes of EGFR tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced EGFR-mutated non-small cell lung cancer
T Isono, J Hasemi, A Hasegawa, T Nishida, C Hosoda… - 2022 - scholar.archive.org
Purpose No clinical trial has compared osimertinib with afatinib. We reviewed clinical data of
patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer …
patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer …
Dramatic Growth of a Vestibular Schwannoma After 16 Years of Postradiosurgery Stability in Association With Exposure to Tyrosine Kinase Inhibitors
LP Carlstrom, A Muñoz-Casabella, A Perry… - Otology & …, 2021 - journals.lww.com
Background: Vestibular schwannoma (VS) is a benign nerve-sheath tumor that sporadically
displays aggressive behavior–often attributable to intrinsic tumor biology and an …
displays aggressive behavior–often attributable to intrinsic tumor biology and an …